7-Ketocholesterol activates caspases-3/7, -8, and -12 in human microvascular endothelial cells in vitro.
7-Ketocholesterol (7kCh) is a major oxysterol found associated with vascular diseases. Human microvascular endothelial cells (HMVECs) were cultured with different concentrations of 7kCh with and without inhibitors. Cell viabilities and caspase activities were assessed. 7kCh caused loss of cell viability in a dose-dependent manner. Caspases-8, -12, and -3/7 but not caspase-9 were activated by 7kCh treatment. The 7kCh-induced caspase-8 activity was blocked partially by pre-treatment with z-VAD-fmk and z-IETD-fmk, a caspase-8 inhibitor. However, pre-treatment with z-ATAD-fmk, a caspase-12 inhibitor, followed by 7kCh exposure lead to significantly increased caspase-8 activity. This suggests that caspase-8 and caspase-12 pathways have unique inhibition patterns and that caspase-12 is likely not upstream and feeding into caspase-8 but the pathways may function in parallel to each other. Caspase-3/7 activation was inhibited partially by low density lipoprotein (LDL), high density lipoprotein (HDL), z-VAD-fmk (pan-caspase inhibitor), and low doses (0.01 and 0.001 microM) of the cholesterol lowering drug, simvastatin. However, only LDL partially protected against 7kCh-induced loss of cell viability suggesting that caspase-independent pathways also contributed to the cell loss and that protection from oxysterol damage may require inhibition of multiple pathways. Moreover, our data suggest that oxysterols such as 7kCh can damage HMVECs cells in part via caspase-dependent apoptosis and may play a role in vascular and retinal diseases.
Luthra
Saurabh
S
Ophthalmology, Drishti Eye Centre, Dehradun, India.
Dong
Joyce
J
Gramajo
Ana L
AL
Chwa
Marilyn
M
Kim
Dae W
DW
Neekhra
Aneesh
A
Kuppermann
Baruch D
BD
Kenney
M Cristina
MC
D000590:Amino Acid Chloromethyl Ketones / Q000494:pharmacology; D000924:Anticholesteremic Agents / Q000494:pharmacology; D002196:Capillaries / Q000187:drug effects* / Q000201:enzymology; D061945:Caspase Inhibitors; D020169:Caspases / Q000096:biosynthesis*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002790:Cholesterol 7-alpha-Hydroxylase / Q000037:antagonists & inhibitors*; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000201:enzymology; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D007653:Ketocholesterols / Q000494:pharmacology*; D008075:Lipoproteins, HDL / Q000494:pharmacology; D008077:Lipoproteins, LDL / Q000494:pharmacology; D019821:Simvastatin / Q000494:pharmacology; D012867:Skin / Q000098:blood supply
D000590:Amino Acid Chloromethyl Ketones; D000924:Anticholesteremic Agents; D061945:Caspase Inhibitors; D015853:Cysteine Proteinase Inhibitors; D004791:Enzyme Inhibitors; D007653:Ketocholesterols; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; C096713:benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; D019821:Simvastatin; D002790:Cholesterol 7-alpha-Hydroxylase; D020169:Caspases; C003001:7-ketocholesterol